Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Ruxolitinib combined with P-gemox in adult patients with newly diagnosed aggressive natural killer cell leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JQJiejing QianWYWenjuan YuDZDe Zhou

Discussion

Loading...

Member takes

Overview

Pilot trial shows 83.3% overall response rate in adults with aggressive natural killer cell leukemia, indicating potential for improved outcomes with ruxolitinib and P-gemox.

Key Points

  • The combination of ruxolitinib and P-gemox achieved an overall response rate of 83.3% after one cycle.
  • Six patients were Epstein-Barr virus positive, with 85.7% presenting hemophagocytic lymphohistiocytosis.
  • Combining therapy involved ruxolitinib, gemcitabine, and oxaliplatin administered over six cycles.
  • Further evaluation in larger studies is warranted to confirm efficacy and safety, given the promising results.

Cite This Study

Qian et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d73dhttps://doi.org/10.1182/blood-2025-7149
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ruxolitinib in malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH): A systematic literature review2025
  2. 2An open-label phase I study of JAK inhibitor ruxolitinib with and without CTLA-4 ig abatacept for the prophylaxis of graft-versus-host ddsease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplantation2025
  3. 3Ruxolitinib combined with decitabine-intensified modified busulfan/cyclophosphamide conditioning regimen reduces relapse after allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia2025
  4. 4Preclinical efficacy of the synergistic Ruxolitinib–Homoharringtonine combination in TP53-mutated myeloproliferative neoplasms progressing to sAML2025
  5. 5Retrospective analysis of ruxolitinib as induction treatment in pediatric hemophagocytic lymphohistiocytosis2025 · 1 citations